Author: oncologs.com

PLYMOUTH MEETING, PA [March 20, 2024] — The National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers—is pleased to announce that Taneal D. Carter, MS, MPA, has been named one of 2024’s ‘40 Under 40’ by the National Minority Quality Forum (NMQF). Every year,

Milan, Italy: Patients with triple-negative breast cancer do not benefit from the addition of atezolizumab to their post-surgery chemotherapy treatment, according to the results of a large phase 3 clinical trial presented at the 14th European Breast Cancer Conference. Triple negative breast cancer, so-called because

Milan, Italy: New data from the KEYNOTE-756 phase 3 clinical trial show that adding the immunotherapy drug, pembrolizumab, to chemotherapy before and after surgery for breast cancer leads to better outcomes for patients regardless of their age or menopausal status. Credit: Prof. Javier Cortes Milan,

Milan, Italy: Researchers have developed a genetic test that can identify how patients with triple negative early-stage breast cancer will respond to immunotherapy drugs. This means that patients who are unlikely to respond to these drugs can avoid the adverse side effects associated with them

Some animals possess the remarkable ability to regenerate lost structures, exemplified by a lizard regrowing its tail. However, this regenerative process must be tightly regulated by the body to ensure proper tissue organization and to prevent abnormal growths, such as cancer. Yet, the precise mechanisms

(Memphis, Tenn – March 19, 2024) MYCN is a gene associated with cell proliferation and growth, which is mutated in many types of cancer. Scientists at St. Jude Children’s Research Hospital studying high-risk neuroblastoma found that MYCN plays a role in modifying the cellular state,

AMHERST, Mass. – There is a surprising dearth of research about how breast cancer cells can go dormant, spread and then resurface years or even decades later, according to a new review of in vitro breast cancer studies conducted by researchers at the University of

(MEMPHIS, Tenn. – March 19, 2024) Fibrolamellar carcinoma (FLC) is a rare liver cancer with a poor prognosis if not addressed early with surgery. The disease is caused by a single genetic mutation that creates a fusion protein. Scientists at St. Jude Children’s Research Hospital

Barcelona, 19 March 2024 – Pediatric cancer, also known as developmental cancer, is rare. Around 400,000 new cases are diagnosed worldwide each year. The likelihood of a child developing two independent cancers during childhood is extremely low. However, such cases do occur, and studying the

“Here I will re-introduce the notion of preemptive combinations (PC) of targeted drugs.” Credit: 2024 Blagosklonny. “Here I will re-introduce the notion of preemptive combinations (PC) of targeted drugs.” BUFFALO, NY- March 19, 2024 – A new research perspective was published by Mikhail V. Blagosklonny